Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition - Narrative (Details)

v3.23.2
Revenue Recognition - Narrative (Details)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
segment
Jun. 30, 2022
USD ($)
Revenue from Contract with Customer [Abstract]        
Number of operating segments | segment     2  
Pharma contract liability, revenue recognized $ 1.7 $ 1.0 $ 3.5 $ 4.1
Amortization of contract commissions $ 0.3 $ 0.2 $ 0.5 $ 0.3